Anti-CD18 [1B4]

Absolute Antibody

Anti-CD18 [1B4]

7

The main application 1B4 has been proposed for is its anti-inflammatory activity. It has been shown to work as a Fab fragment prepared by papain digestion (Wright et al, 1983). Its binding to antigen was confirmed by RIA (Van Voorhis et al, 1983). 1B4 has been shown to work in Rhesus monkeys, and has reduced immunogenicity once humanized. 1B4 is also compatible with immunofluorescence which has been used to demonstrate that the fine specificity of the combining sites was not altered by humanization (Singer et al, 1993). It has been shown to prevent polymorphonuclear (PMN)-dpepndent pathology in animal models of hemorrhagic shock, dermal inflammation, reperfusion injury, IBD and meningitis (Vedder et al, 1988, Vedder et al, 1990, Mileski et al, 1990, Carlos et al, 1990, Tuomanen et al, 1989, Arfors et al, 1987, Wallace et al, 1991, Wallace et al, 1992). The glycosylation patterns of 1B4 have also been studied in detail using NMR, ES-MS, HPAEC-PAD mapping and glycosyl composition analysis (Yu Ip et al, 1994).

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, ELISA, RadioImmunoAssay

RIA; IP; ELISA; IF; FC

Research Use Only

Monoclonal

1B4

ITGB2

integrin subunit beta 2

CD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; integrin beta chain, beta 2; integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); LAD; LCAMB; leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C; LFA-1; MAC-1; MF17; MFI7; truncated integrin beta-2

Human

IgG1

Integrin beta-2

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Human, Rhesus Monkey

Blood was obtained from 4 helathy donors and the mononuclear cells harvested and grown. A BALB/c mouse was injected with 10^6 monocytes three times at monthly intervals, and four times with 5x10^6 monocytes oon each of the four days before fusion. The spleen cells were then fused to P3U1 myeloma cells to generate hybridomas and RIA was used to identify lines of interest.

-20°C,2°C to 8°C

12352203